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Abstract Alzheimer’s disease (AD) is among themost significant health care burdens. Disappointing results
from clinical trials in late-stage AD persons combined with hopeful results from trials in persons with
early-stage suggest that research in the preclinical stage of AD is necessary to define an optimal
therapeutic success window. We review the justification for conducting trials in the preclinical stage
and highlight novel ethical challenges that arise and are related to determining appropriate
risk-benefit ratios and disclosing individuals’ biomarker status. We propose that to conduct clinical
trials with these participants, we need to improve public understanding of AD using unified
vocabulary, resolve the acceptable risk-benefit ratio in asymptomatic participants, and disclose or
not biomarker status with attention to study type (observational studies vs clinical trials). Overcoming
these challenges will justify clinical trials in preclinical AD at the societal level and aid to the
development of societal and legal support for trial participants.
 2016 The Authors. Published by Elsevier Inc. on behalf of Alzheimer’s Association. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
By the year 2030, 76 million people worldwide will
suffer from dementia, with most cases being caused by
Alzheimer’s disease (AD) [1]. Despite the considerable
advances in our understanding of the neuropathologic
processes that underpin AD, academic and industry research
programs that develop mechanism-based therapies,
including those directed against b-amyloid have yet to
produce meaningful clinical benefits [2]. Consequently,
one of the biggest questions that the AD research community
faces is whether clinical trials have so far included
participants who have already surpassed the optimal
therapeutic window for intervention, together with the
need to ensure the presence of AD pathology through
biomarkers.
In 1984, the National Institute of Neurological and
Communicative Disorders and Stroke-Alzheimer’s Disease
and Related Disorders Association (NINDS-ADRDA, now
the Alzheimer’s Association) published for the first time
the clinical diagnostic criteria for AD [3]. Almost 30 years
later, the progress in our scientific understanding of
the neuropathology that precedes clinical symptoms
prompted the scientific community to redefine AD as a
pathologic continuum. Both the International Working
Group and the US National Institute of Aging with the
Alzheimer’s Association (NIA-AA) released revised
guidelines that incorporated biomarkers to identify
individuals at risk of developing AD dementia [4–8]. Both
criteria subdivide AD development into three stages:
preclinical (abnormal biomarkers and no or only subtle
cognitive impairment), mild cognitive impairment (MCI)
due to AD or prodromal AD (defined as the presence of
abnormal pathophysiological biomarkers and episodic
memory impairment) and dementia (abnormal biomarkers
and clear cognitive and functional impairment).
One significant advance in our understanding of AD is
that it has two components: a neuropathologic one, which
remains asymptomatic during years, and a clinical one,
which starts with a MCI stage followed by a dementia one.
Convergent biomarker and imaging findings from autosomal
dominant AD mutation carriers, genetic at-risk and age
at-risk cohorts suggest that the pathophysiological process
of AD starts over a decade before the dementia stage
[9–14]. This asymptomatic phase, referred to as preclinical
AD, has given us an unprecedented opportunity to perform
observational studies and trials to intervene at earlier
stages of the continuum and delay the onset of clinical
decline and ultimately dementia. In this scenario, trials in
mild moderate AD have been consistently negative during
the last decade [15], and although we are still waiting for
the results of ongoing prodromal AD trials, intervention
studies on asymptomatic individuals appear as highly
relevant and promising, before substantial irreversible
neuronal network dysfunction and loss, associated with
overt clinical symptoms, have occurred.
Conducting preclinical AD trials gives rise to a variety
of novel ethical and policy challenges. These include
whether to disclose genetic and/or biomarker results to an
individual, the need to determine an acceptable risk-benefit
ratio in asymptomatic participants and the legal protection
of participants from insurance policies. The ethical
framework that guides clinical research can be seen as a
balancing among the interests of the participants and society
on one side, as well as the research challenges on the other
[16]. To review and discuss the novel ethical challenges
that need to be overcome for successful performance of trials
in the preclinical stage of AD, a multistakeholder group met
in a 1-day summit entitled “Ethical challenges of future
Alzheimer’s disease clinical research” held in Barcelona in
October 2014. This reunion was organized by the Barcelona-
beta Brain Research Center, the research institute where the
Pasqual Maragall Foundation conducts all its scientific
activities devoted to clinical research for the prevention of
AD. This discussion group included experts from academia,
including AD researchers and bioethicists, patients’
organizations and regulatory agencies. This article summa-
rizes the outcome of that meeting, where these ethical and
policy challenges were debated and recommendations to
address them throughout the research process were
proposed, discussed, and agreed.
2. The scientific basis of the preclinical stage and
prevention strategies
The prevailing hypothesis for AD pathogenesis, the
amyloid cascade hypothesis, assumes several causal events
that begin with the accumulation of b-amyloid in the brain
followed by tau hyperphosphorylation and then neuronal
degeneration. In addition to advanced age, the risk of
developing AD is increased among persons with certain
genetic variants. Autosomal dominant AD (ADAD),
characterized by pathogenic mutations in one of three
genes—the b-amyloid precursor protein (APP), Presenilin
1 (PSEN1), and Presenilin 2 (PSEN2)—provide almost
certain risk (w100%) of developing symptomatic AD
[17]. In addition, apolipoprotein E ε4 (APOE ε4)
allele carriers have a significantly higher risk of developing
symptomatic AD when compared to noncarriers [18].
Specifically, the risk of AD has been shown to be 2.6 times
higher for people with the APOE ε2/ε4 genotype relative to
APOE ε3/ε3 individuals and 3.2 and 14.9 times higher for
APOE ε3/ε4 and APOE ε4/ε4 persons, respectively [19].
Our understanding of preclinical AD indicates that
biomarker abnormality occurs in a temporal manner where
it has been demonstrated that abnormally low cerebrospinal
fluid (CSF) b-amyloid 42 (Ab42) and cerebral amyloid
deposits precede elevated CSF tau, topographical cerebral
injury, and cognitive decline [20]. New data from recently
initiated studies such as EPAD (European Prevention of
Alzheimer’s Dementia), PREVENT Research Programme
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(UK and France), and ALFA (Alzheimer and Family; Spain)
will further support these disease models. The timeframe for
these pathologic changes may be as long as 25 years before
symptom onset. In presymptomatic ADAD individuals, CSF
Ab42 decline has been observed 25 years before clinical
symptoms, whereas b-amyloid deposition (measured by
amyloid imaging) and elevated CSF tau have been detected
15 years before symptom onset [9]. The preclinical stage
of AD can be further subdivided into three stages:
stage 1—asymptomatic amyloidosis (positive amyloid
imaging, low CSF Ab42); stage 2—amyloidosis and
neurodegeneration (neuronal dysfunction; high CSF tau);
and stage 3—amyloidosis, neurodegeneration, and subtle
or subjective cognitive decline (this decline has yet to be
operationalized but presumably falls short of prodromal
AD or MCI due to AD) [8]. The validity of these
stages has been suggested by a retrospective study of
asymptomatic individuals which demonstrated that the
5-year progression rate was 2% for participants classified
as normal, 11% for those in stage 1, 26% for stage 2, and
56% for stage 3 [14].
Retrospective and prospective studies are useful to
indicate the likely causal pathways that lead from a healthy
aging brain to a diseased brain, but they cannot definitively
establish the validity of these pathways. The best method
to establish this validity is to intervene using a randomized
and controlled experiment with an antiamyloid drug in
asymptomatic persons who exhibit amyloid-positive PET
scans, before substantial loss of synaptic and neuronal
integrity. In that sense, the only way to validate the causality
of a pathway is through a clinical trial in which the active
drug is able to prevent the deleterious effect of the proposed
pathogenic process. Hence, a positive prevention trial not
only validates the efficacy of the drug but also the causality
of the treated pathway. This model has been used in other
diseases where treatment in asymptomatic individuals has
resulted in significant benefit for patients and society. For
instance, in the United States, 28% of the population aged
40 years and over uses cholesterol-lowering medication on
a regular basis. The appropriate widespread use of these
medications has with no doubt prolonged the lives of
millions [21]. The origin of these drugs was a pioneer
study in asymptomatic familial hypercholesterolemia
patients [22].
In our field, to arrest or at least delay, the onset of cogni-
tive decline in subjects showing amyloid accumulation is
termed secondary prevention. On the other hand, primary
prevention strategies directed toward preventing the initial
cortical amyloid deposition would significantly impact the
prevalence of AD. Secondary prevention clinical trials in
persons with preclinical AD that are biomarker positive
and asymptomatic are already occurring and summarized
here in Table 1 [23–26]. Collectively, these studies will
help ascertain if secondary prevention is a valid approach
for AD, and whether clinical trials of 3 to 5 years are
sufficient for delaying cognitive decline [27]. Recent
worldwide initiatives are also aiming to maximize efficiency
to obtain a clinical signal and develop sensitive outcomes for
detecting early decline, through new trial designs. The first
of these initiatives, funded by the Innovative Medicines
Initiative under the topic “European platform for proof of
concept for prevention in Alzheimer’s disease” is the
EPAD project. This project aims at delivering an adaptive
trial for secondary prevention of AD. Sister initiatives in
the upcoming years will be launched in the United States
and Canada.
The motivation for secondary prevention trials in AD
dementia is based on the observation that delaying the onset
of AD dementia by as little as 5 years would decrease the
total number of Americans aged 65 years and older with
AD from 5.6 million in 2010 to 4 million by 2020 [28].
Longitudinal studies have shown that as many as
30%–40% of elderly healthy individuals exhibit signs of
b-amyloid accumulation [29]. In addition, many individuals
with b-amyloid and tau accumulation exhibited subtle
cognitive decline antemortem [30]. Furthermore, several
studies have also shown that cognitively normal individuals
with abnormal levels of AD biomarkers exhibit longitudinal
cognitive decline [31,32]. These individuals are at an
increased risk for progressing to cognitive impairment
[33,34].
3. The ethical challenges
When considering preclinical AD trials, two ethical
issues of special importance arise. First, because asymptom-
atic persons are exposed to novel agents for an extended
period, the design of the trial must ensure that the potential
benefits justify the burden and risk for the participants.
Second, many prevention trials will enrich their study
population through genetic and other biological risk factors
that will be screened by genetic and/or imaging techniques.
As these tests are normally discouraged in routine clinical
practice and therefore, a person would not normally receive
this information unless participating in prevention trials, the
issue of disclosure of such information must be carefully
addressed [35–37].
3.1. Risk-benefit considerations
One of the issues we face when considering the clinical
therapeutic window for preclinical studies is that the earlier
we are in the disease process, the longer clinical trials aimed
to detect change will have to last. On a practical level, this
will result in screening an increased number of participants
to find the right population and longer follow-up times to
detect change. For example, the A4 study estimates that to
enroll over 1000 individuals, over 5000 people must be
screened, around 3000 will have to undergo PET amyloid
imaging, and that it will take 3 years to detect any effect
of the treatment [25]. If future longitudinal studies in
preclinical individuals involve widening the biomarker
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status to incorporate individuals with lower biomarker
levels, the number of participants needed and the length of
follow-up are likely to increase.
Overall, future longitudinal studies that prolong partici-
pants’ exposure to interventions will place a significantly
greater procedural burden on individuals; the longer these
studies last, the greater the procedural burden will be. Based
on the current biomarker technologies and the regulatory
landscape, enrolling participants with even lower levels of
b-amyloid accumulation (compared to current studies) will
require an evaluation of what level of risk is ethical to offer
as a potential exposure.
One important factor in determining the acceptable
risk-benefit ratio is to better understand the public’s values
regarding this issue. However, this will require improving
public understanding of the relevant issues, such as the
probabilistic over deterministic nature of biomarkers. This
may be accomplishable through public messaging and other
educational methods. Indeed, the history of developing
treatments for serious and life threatening disease such as
AIDS and multiple sclerosis (MS) shows how decisions
about what risks are acceptable in the pursuit of a treatment
are part of a negotiated social order that engages expert
clinicians, regulators, and patients. In the case of AIDS,
the patient community moved trialists and regulators to
adopt trial designs that might expose subjects to more active
intervention-derived risk but at the same time expedited the
discovery of whether an intervention was effective [38].
Input from patient advocates was also influential in the
FDA’s decision to permit natalizumab as a treatment for
MS despite the risk of progressive multifocal leukoence-
phalopathy ([39]; note “There is an active ongoing
discussion among regulators, researchers, and patient advo-
cates seeking successful ways to continue development of
promising drugs while limiting the hazard to patients who
take these medications.”) In a similar manner, input from
the patient community can help the AD research community
understand what degree of risk is acceptable when drugs
may, for example, present risks to brain function from side
effects such as amyloid-related imaging abnormalities.
A basic ethical principle in clinical research is “respect
for persons”, recognizing that some individuals are not
autonomous, which sometimes can be the case among
Alzheimer’s patients. The requirement for informed consent
is designed to uphold this ethical principle and is based on
clear language and unbiased information on the issue at
stake. One benefit of conducting trials in preclinical AD
(over studies with symptomatic individuals) is that asymp-
tomatic persons are in a much better position to protect their
own welfare and to express their values regarding what risk
is acceptable for them in providing informed consent. We
know that people volunteer for clinical trials for a variety
of reasons and indeed, the distinct types of benefit
outcomes from research (namely direct, collateral, and
aspirational) must be specifically specified when obtaining
the participants informed consent [40]. One perceived
benefit of interventional trials is the possibility of
receiving an efficacious therapeutic agent or combination
of agents/interventions (direct benefit). Hence, individuals
enroll in research because they consider it may be of benefit
to their own health, and this benefit outweighs the risks of the
research. Furthermore, there may be associated indirect
potential benefits for clinical trial participation (collateral
benefit). For example, participation may yield positive
psychological impact on self-confidence, self-worth, and
the perceived benefit that the volunteer provides societal
value [41] and even free physical examination and testing.
In addition, it has also been shown that altruism (aspirational
Table 1
Secondary prevention clinical trials in Alzheimer’s disease
Descriptor DIAN-TU API-ADAD A4 TOMMORROW API-APOε4
Target population Autosomal dominant AD Autosomal dominant AD Cognitively normal,
beta-amyloid
positive
Cognitively normal with
genetic risk
Cognitively normal
with genetic risk
Specific
characteristics
ADAD mutation carriers PSEN1 E280 A mutation
carriers
Positive brain
amyloid PET
TOMM40/APOE genotype Homozygous
APOε4 genotype
Estimated
enrollment
210 300 1150 5800 1340
Phase Phase II/III Phase II Phase III Phase III Phase II/III
Compound Gantenerumab,
Solanezumab
Crenezumab Solanezumab Pioglitazone CAD106, CNP520
Mechanism Anti-Ab antibodies Anti-Ab antibody Anti-Ab antibody PPAR-g agonist Ab vaccine & BACE
inhibitor
Status Recruiting Recruiting Recruiting Recruiting Not yet recruiting
Primary outcome Composite cognitive
test score
Composite cognitive test
score
Composite cognitive
test score
Time to diagnosis of MCI
due to AD
Time to diagnosis of
MCI due to AD,
composite cognitive
test score
Study duration 4 years 5 years 3 years 5 years 5 years
Study identifier NCT01760005 NCT01998841 NCT02008357 NCT01931566 NCT02565511
Reference Moulder et al., 2013 [23] Reiman et al., 2011 [24] Sperling et al., 2014 [25] Roses et al., 2014 [26] Reiman et al., 2011 [24]
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benefit)—that is, potential benefit to their relatives, to future
sufferers or to society—also may be a perceived benefit of
entering a clinical trial [42].
3.2. Disclosure of risk marker status
Another fundamental consideration that is integral in the
ethical assessment of clinical research is the potential harm
and benefit of disclosure [35–37]. Although genetic testing
and biomarker status differ in several ways such as
imminence of risk, stability of the results, and direct
implications for consanguineous family members [37],
disclosure of any genetic or biomarker status is a complex
task that requires specific training and ability to convey
uncertainty. Therefore, discussing the risks and benefits of
disclosure can largely be regarded as indistinguishable
between genetic and biomarker disclosure. It has already
been shown that knowledge imbalances between scientific
and medical concepts related to genetics as well as medical
practices can occur, even in study populations with a
relatively high educational status and genetic knowledge
[43]. When considering disclosure, the physician or
researcher has the responsibility of educating the patient
on the risks and benefits of learning their genetic/biomarker
status. In the Risk Evaluation and Education of AD
(REVEAL) study, pictures, graphic illustrations, and
animations are used to explain the risk of developing AD,
especially in cases when there is a genetic predisposition
[44,45].
The decision to learn one’s genetic or biomarker status is
that of the study participant, especially in trials in which
participants are cognitively normal. From an ethical
standpoint, the concern with disclosing a person’s biomarker
status is that this could induce psychological stress. Previous
studies that have examined the impact of genetic disclosure
have found that there are no overall significant differences in
the levels of anxiety experienced by individuals who learn
their APOE status compared to individuals who do not learn
this information [46]. Nevertheless, those who were
informed that they were APOE ε4 noncarriers had a
significantly lower level of test-related distress. In this
case, the study was performed over the course of 1 year;
however, when considering preclinical studies that may
last for many years during which participants are implicitly
reminded of their genetic or biomarker status, the burden of
knowing one’s status must be thoroughly studied for AD. In
that sense, the preclinical and early diagnoses of
Huntington’s disease (HD) are associated with an increased
risk of suicidal behavior. On the other hand, this figure
coincides with the suicide rates previously reported for
symptomatic individuals diagnosed with HD [47].
Therefore, more studies are necessary to prevent this harm
from being neglected.
Another consideration in whether to disclose genetic or
biomarker results is the concept of a stereotype threat
whereby providing a label to the individual elicits behavior
and/or characteristics that are perceived as belonging
to this label. This is illustrated in a recent study where
APOE ε4 carriers who were told had poorer performances
on cognitive tests compared to their nondisclosure counter-
parts who carried the same alleles [48].
Given the potential adverse effects of knowing one’s risk,
should the AD research community always conduct trials
that do not disclose gene or biomarker results? In answering
this question, it is important to examine the public’s
perception of predictive testing (with the assumption of
receiving the results). An Alzheimer Europe survey of
random samples from five different countries found that
approximately two-thirds of respondents would get a
medical test which would tell them whether they would
get AD before they had symptoms [49]. In addition, other
studies have shown that disclosure of an “at-risk” status
can also positively impact peoples’ lives. Studies that
followed-up disclosure groups found that APOE ε4
carriers more frequently took measures to reduce risk,
compared to APOE ε4 non-carriers, implementing health-
related behavioral changes [50,51].
Research designs that disclose risk information can
further protect subjects by implementing safeguards. Before
disclosing genetic or biomarker status, the investigator
ought to assess if the potential participant is emotionally
capable of enrolling in a study. Data from the REVEAL
study clearly show that those who exhibited a high degree
of emotional stress before undergoing genetic testing were
more likely to have emotional difficulties after disclosure
[46], although this does not preclude those subjects for
participating in a study. Furthermore, for those who are
included, one way to reduce potential stress is to provide
continuous counseling throughout the study or through
social forums where open discussions can take place as
this has been shown to have a direct positive effect on stress
and anxiety [52].
Briefly, the main risks deriving from disclosure include
placing a cloud of uncertainty over participants that may
affect their daily lives and/or performance in specific
procedures and the complexity of conveying uncertainty.
On the other hand, main benefits comprise the protection
of biomarker-negative individuals from risks and harms
related to clinical studies’ procedures, and the positive
impact that this information may have on people’s lives.
According to these appreciations, we recommend to disclose
or not biomarker status with attention to study type
(observational studies vs clinical trials; see below).
When considering the prospect of long-term preclinical
studies, we recommend that for observational studies, unless
the aim of the study is to investigate the impact of
disclosure on outcome, the most scientifically valid method
is a blinded enrollment study in which genetic or biomarker
status is not disclosed. This will avoid the impact of knowing
on participants’ welfare and cognitive performance, together
with disclosing clinically nonrelevant biomarker or genetic
status of uncertain prognosis.
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For interventional studies, protecting the subjects that
are biomarker negative from risks and harms related to
the trial’s procedures prevail over the motivations noted
above to support blinded enrollment. Furthermore, a recent
systematic analysis comparing the ethics of transparent
(i.e., requiring disclosure) enrollment versus blinded
enrollment in AD prevention studies provided strong
arguments that there are no special risk benefit, informed
consent, or fair participant selection issues that require
blinded enrollment. Therefore, if it is feasible to conduct
a scientifically valid trial with a transparent enrollment
study design, we recommend this design for interventional
studies. Exceptionally, the feasibility of a transparent
design will depend on the characteristics of the study pop-
ulation. In the DIAN-TU study, the potential participant
pool is quite small consisting of relatively young persons
at risk for familial AD. For such persons, whether to learn
that they will almost certainly develop AD at a relatively
young age is a very momentous and complex question. It
has been the case that even when offered the opportunity
to have genetic counseling and commercial genetic testing
to learn their mutation status at no cost to themselves, the
majority decline as they do not wish to know, as has been
the case in similar populations in previous studies [53–55].
Thus, it would not be feasible to conduct a scientifically
valid study involving DIAN-TU registry participants using
a transparent enrollment (i.e., requiring disclosure of
genetic status).
By contrast, the A4 trial draws from a large pool of poten-
tial participants who have an elevated probabilistic increase
in risk for AD and requires that the participants are willing to
learn their amyloid biomarker status. Most of the partici-
pants are in a much later stage of life and may in fact have
a greater motivation to learn about factors that may increase
their risk of AD. Thus, the feasibility of a transparent enroll-
ment design is much greater. This has been confirmed in our
experience so far in the A4 trial [56,57].
An important additional argument for the transparent
design (i.e., requiring gene or biomarker disclosure) is that
this design better reflects the future clinical practice of
drug prescription to those who learn that they have an altered
AD biomarker. A design that includes biomarker disclosure
would therefore more closely resemble routine clinical prac-
tice and so can provide information about the success of this
potential clinical future. Furthermore, blinded designs
require risk-negative participants to be enrolled to avoid
“disclosure by enrollment”; thus, transparent enrollment
has the advantage of minimizing the number of participants
enrolled to attain sufficient statistical power to obtain clini-
cally meaningful results. New trials currently under design,
like the new API trial with APOE ε4/ε4 homozygotes, will
be disclosing APOE status, through a standardized genetic
counseling protocol [46].
Finally, we know that AD manifests its pathology years
before it manifests its clinical symptoms and hence, from a
biological perspective, the disease is already present and
the term preclinical AD is accurate. Nevertheless, we have
to be especially careful in how we address and communicate
the preclinical stage of the disease to study participants. Tak-
ing into account that not all participants in preclinical studies
will develop the clinical symptoms of the disease, one useful
term to address them could be asymptomatic at risk for
cognitive impairment.
4. Social, legal, and policy challenges
The foremost ethical obstacle that we, as a society, need
to overcome involves the concept of social justice—namely,
justice in terms of the distribution of wealth, opportunities,
and privileges within a society. Can one therefore justify sec-
ondary prevention as a priority for the public administration
when there is insufficient support and treatment for indivi-
duals that suffer from dementia? Indeed, we envisage that
conducting trials in preclinical AD will increase the overall
awareness of AD that should, in turn, improve support and
treatment for current AD sufferers. Nevertheless, currently,
between half and three quarters of people with dementia
have no formal diagnosis [58–60]. Furthermore, for those
that are diagnosed with AD many do not receive their
diagnosis, and for those that do it there can be a
substantial delay between diagnostic tests and receiving
the diagnosis [61,62]. In a recent special report of the
Alzheimer’s Association Facts & Figures, only 45% of
individuals diagnosed with Alzheimer’s disease were
notified of their diagnosis.
The first step to achieve this is the need to develop a
uniform language (currently under development by
expert committees through both the Alzheimer’s
Association and Alzheimer’s Europe) to reinforce a single
message to the public and policy makers. By unifying the
message from clinical research, we can increase the
awareness of AD clinical trials taking place. Increasing
awareness will improve public understanding toward
the severity of the disease as it has been shown that
individuals with close personal ties to patients with AD are
more likely (than those without) to view AD as a major
concern [63]. Consequently, this will not only reduce the
number of undiagnosed individuals but will also serve to
improve willingness to pursue predictive genetic and
biomarker testing that may facilitate future asymptomatic
enrollment.
Changing the public perception of AD and predictive
testing also requires the introduction of legal changes to
protect prospective participants. Currently, there is limited
protection for individuals who wish to participate in
preventative clinical trials. For example, in the United
States, the Genetic Information Nondiscrimination Act
(GINA) prohibits discrimination by health insurers or
employers based on genetic information. GINA protects
individuals with known genetic markers who have not
demonstrated “disease manifestation” of a condition that is
consistent with the genetic marker [64]. By contrast,
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European protection of an individual’s genetic information
differs among governments [65]. The legal mechanisms
for reacting against breaches of the right to privacy in
Europe are based on Directive 95/46/CE. However, this
Directive has been differently transposed in different
member states. Although in some countries (such as
Belgium, Spain, and the Netherlands), privacy is
recognized as a constitutional right, others such as Germany,
Italy, Denmark, and France do not have this specific
recognition.
At present, there are no legal safeguards that protect an
individual’s biomarker data and without adequate
protection, the prospect of participating in a secondary
prevention trial may significantly impact an individual’s
ability to have access to an adequate health insurance,
insurance coverage, and working potential. To implement
change, governmental bodies will need to first recognize
biomarkers through policy bodies such as the FDA (Food
and Drug Administration) and EMA (European Medicines
Agency). At the time of writing, both the FDA and the
EMA are preparing guidelines on the use of biomarkers in
AD preclinical research. The outcome of these efforts will
play an important role in future health and legal policy for
AD research. In addition, current prevention studies,
together with future ones, will provide information of the
meaning of a positive beta-amyloid PET scan that may
change with the gain of further knowledge, and education
about the risks and benefits of beta-amyloid PET imaging,
assess the participant’s readiness and willingness to receive
the result and, where positive results are disclosed, monitor
the individual’s well being. An investigator taking part in
such research has the responsibility to make sure that the
study is taking steps to minimize disclosure of the result in
the medical record, and the participant should feel free to
ask whether this is the case.
One final challenge that faces the future of trials in
preclinical AD is the financial cost of such research
initiatives. The patent life gives the manufacturer a
maximum of 20 years of exclusive ownership since initial
filing. If preclinical AD trials are to last around 5 years,
the likelihood that pharmaceutical companies can fund
them and achieve profit from successful therapeutic agents
is improbable. Therefore, it is very likely that public
financial support will be required to complement private
funding to support future AD clinical trials. Developments
to tackle this challenge are already a reality in the United
States and Europe. In the United States, both DIAN-TU
[23] and API are the result of a public-private partnership;
whereas in Europe, the EPAD project aims to deliver a
standing, adaptive, multiarm proof of concept study for early
and accurate decisions on a candidate compound’s (or
combination of compounds) ongoing development for the
prevention of Alzheimer’s dementia [66]. We reason that
such distributed infrastructures that support clinical research
for societal gain will be essential for the future of AD
research.
5. Conclusions
Studies and trials in preclinical AD have a solid scientific
basis and hold significant promise as part of the future AD
research landscape. In this scenario, a number of ethical
challenges, mainly related to determining appropriate risk-
benefit ratios and disclosing individuals’ biomarker status,
arise. Determining the acceptable risk-benefit ratio will
require improving public understanding of the relevant
issues, such as the probabilistic over deterministic nature
of biomarkers. Finally, we consider that both blinded obser-
vational trials and transparent interventional trials should be
considered as standard for future studies in this field.
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RESEARCH IN CONTEXT
1. Systematic review: The authors reviewed the litera-
ture using traditional sources. Publications validating
pathophysiological Alzheimer’s disease (AD) bio-
markers and longitudinal studies on Alzheimer’s
pathology that justify the performance of preclinical
studies are cited throughout the manuscript.
2. Interpretation:We identify ethical concerns from asym-
ptomatic AD studies related to risk-benefit ratio and
genetic and biomarker disclosure as substantial ethical
obstacles for preclinical studies.Asymptomatic individ-
uals participating in clinical trials should be educated
on the risks and benefits of participation in order to
determine the ethically appropriate risk-benefit ratio.
3. Future directions: Public engagement, focus groups
and social support using a unified vocabulary will
be essential to improve standards of care for current
AD sufferers and promote predictive testing. Such
educational measures will be fundamental to over-
come societal and legal obstacles and protect individ-
uals from discrimination.
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